Elevated IL-17A concentrations promote vascular fibrosis in systemic sclerosis patients by triggering the ERK1/2 pathway in vascular smooth muscle cells within the dermis (Seki et al., 2024). This evidence concerns the gene IL17A and systemic sclerosis.